Human Thyroid Cancers Preclinical and Translational Research Laboratory
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, MA

Carmelo Nucera, MD, PhD
Assistant Professor at Harvard Medical School
Principal Investigator Human Thyroid Cancers Preclinical and Translational Research
Specialist in Endocrine Diseases and Metabolism
Experimental Division of Cancer Biology and Angiogenesis
Department of Pathology
Beth Israel Deaconess Medical Center
Simon C. Fireman Research Center
Harvard Medical School
99 Brookline Avenue
Office Room: RN-0270A
Email 1: cnucera@bidmc.harvard.edu
Office-Phone: 617-667-5964
Lab-Phone: 617-667-1696
Fax: 617-667-3591
Boston (MA) 02215, USA

My laboratory is open to accept undergraduate students. I'm genuinely dedicated to mentor undergraduate students and advancing translational Thyroid Cancer Research and non-coding RNA-based discoveries.

I'm actively committed to mentor and applying my research to patient care, to facilitate innovation for healthcare, solve unmet clinical needs, and ultimately improve public health.

I am an MD/PhD with specialty in endocrine cancers and I'm developing as Assistant Professor at Harvard Medical School a multidisciplinary research program in the "Division of Cancer Biology and Angiogenesis/Experimental Pathology" at the Beth Israel Deaconess Medical Center/Harvard Medical School, focused on "preclinical and translational models of human thyroid cancer with an emphasis on mechanisms of metastatic networks, new models of in vitro angiogenesis, tumor microenvironment, and metabolic regulations, using novel targeted therapies anti-$BRAF^{V600E}$ anti-tumor microenvironment. I am primarily engaged in basic and translational thyroid cancer research, but also actively participate in tutoring and teaching activities to basic science students and medical students. I have more than 10-years of research and clinical experience.
In particular, my research interests are in elucidating mechanisms by which the oncogene $BRAF^{V600E}$ leads to the invasive and metastatic phenotype in aggressive and iodine-refractory thyroid cancers.

I'm highly committed and motivated to applying my research and effort to patient care, to facilitate innovation, to solve unmet clinical needs, and improve public health.

I have been awarded from the American Thyroid Association, the NIH/NCI for Thyroid Cancer Research, Tumor Microenvironment, and $BRAF^{V600E}$.

My translational research and mentoring program is aimed:

(i) To determine the prognostic role of Long intergenic non-coding RNA (LIncRNA) in thyroid cancer.
(ii) To identify new prognostic biomarkers and validate therapeutics for treating metastatic/refractory thyroid cancers.
(iii) To identify pro-metastatic/-angiogenic and metabolic pathways in the microenvironment of $BRAF^{V600E}$-positive thyroid cancer.
(iv) To determine the function of lymphatic/blood vessels in thyroid cancer and identify driver clones in the angiogenic microenvironment of thyroid tumors (tumor heterogeneity).
(v) To investigate pathogenesis and molecular basis of “orphan and rare’ endocrine diseases.

If you are interested in applying to this program please submit your application, a copy of your Curriculum Vitae and email address of 2 references (i.e. Faculty) to:
Carmelo Nucera cnucera@bidmc.harvard.edu